Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This observational study shows PCSK9 inhibitor monoclonal antibodies significantly reduce ischaemic events and mortality over five years in patients with ASCVD but no prior ischemic events, highlighting their preventive potential in routine
This review synthesizes the trajectory of PCSK9 inhibitors, from pivotal monoclonal antibody trials to emerging RNA interference and gene-editing technologies, emphasizing their role in achieving ultra-low LDL-C levels and reducing major ad
This article explores the transformation of lipid management through PCSK9 inhibitors. From genetic discovery to landmark cardiovascular outcomes trials, we examine how monoclonal antibodies, RNA interference, and gene editing are redefinin
In 273,770 US patients with established ASCVD, rising lipoprotein(a) (nmol/L) was steadily associated with higher risk of recurrent events; the excess risk was partially blunted in those receiving high‑impact LDL‑lowering therapy, most nota
In the VESALIUS‑CV trial, evolocumab reduced first major adverse cardiovascular events by 25% (3‑point MACE) and 19% (4‑point MACE) versus placebo over 4.6 years in patients with atherosclerosis or diabetes and no prior MI or stroke.